Cara gains on pruritus data

Cara Therapeutics Inc. (NASDAQ:CARA) gained $3.15 (20%) to $18.99 on Thursday after IV CR845 met the primary endpoint of a Phase II trial to treat uremic pruritus. The long-acting peripheral kappa opioid receptor ( OPRK1; KOR) agonist significantly reduced itch scores from baseline vs. placebo.

In the 65-patient study, patients receiving IV CR845 had a 54% greater reduction vs. placebo in average worst itching as measured by a visual analog scale during the second week of treatment (p=0.016). ...